Increasing Lung Cancer Screening Among Emergency Department Patients - LCS R01
28 de abril de 2026 atualizado por: David Adler, University of Rochester
Increasing Lung Cancer Screening Uptake Among Emergency Department Patients - LCS R01
This randomized clinical trial evaluates the effectiveness of text messaging and facilitated referral strategies to increase lung cancer screening uptake among emergency department patients who meet lung cancer screening eligibility criteria.
Visão geral do estudo
Status
Ainda não está recrutando
Intervenção / Tratamento
Descrição detalhada
This randomized clinical trial will evaluate strategies to improve lung cancer screening uptake among emergency department patients who meet lung cancer screening eligibility criteria based on age and smoking history. Participants will be randomized using a 2 by 2 factorial design into one of four groups: basic referral, basic referral plus text messaging, facilitated referral, or facilitated referral plus text messaging.
The basic referral strategy includes verbal referral to the lung cancer screening program and primary care provider, if applicable, along with written contact information for the lung cancer screening program navigator. The facilitated referral strategy includes submission of a lung cancer screening requisition to the lung cancer screening program on behalf of the participant during the emergency department visit.
The text messaging intervention includes a series of theory informed messages designed to increase intention and motivation to complete lung cancer screening. Lung cancer screening uptake will be assessed at 120 days after enrollment using participant follow up and electronic health record review.
Tipo de estudo
Intervencional
Inscrição (Estimado)
1036
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Peter Macdowell
- Número de telefone: 585-274-1509
- E-mail: peter_macdowell@urmc.rochester.edu
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Age 50 - 80
- ≥ 20 pack-year smoking history
- current smoker or quit within 15 years
- English/Spanish speaking
- Registered in the Emergency Department as a patient
Exclusion Criteria:
- Non-English/Spanish
- Inability to provide consent (e.g. high clinical acuity, cognitive deficit)
- Lack of text-capable mobile phone and/or inability to use text function
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Triagem
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Basic Referral (enhanced control arm)
Participants assigned to this arm will be notified that they are eligible and meet federal recommendations for lung cancer screening.
They will be verbally referred to a lung cancer screening program and their primary care provider (if they have one) to discuss lung cancer screening.
They will also be provided with written materials that include telephone contact information for the lung cancer screening program navigator.
If contacted, the LCS Program Navigator will conduct a discussion, schedule a screening CT scan at one of the 8 regional American College of Radiology-designated lung cancer screening centers and arrange clinical follow-up as needed.
|
Participants are verbally referred to the lung cancer screening program and their primary care provider if applicable.
Written materials with contact information for the lung cancer screening program navigator are provided.
|
|
Experimental: Basic Referral plus Text Messaging
Participants assigned to this arm will receive the basic referral as described in the previous arm.
In addition, they will receive a series of text messages, aimed at generating intention and motivation to get lung cancer screening.
Patients will receive a total of 9 messages.
|
Participants are verbally referred to the lung cancer screening program and their primary care provider if applicable.
Written materials with contact information for the lung cancer screening program navigator are provided.
Participants receive a series of up to 9 theory informed text messages designed to increase awareness, motivation, and completion of lung cancer screening.
|
|
Comparador Ativo: Facilitated Referral
Participants assigned to this arm will be notified that they are eligible and meet federal recommendations for lung cancer screening.
Rather than the basic referral received in the arms above, a lung cancer screening requisition form will be submitted to the lung cancer screening program on behalf of the participant during their emergency department visit.
|
A lung cancer screening requisition form is submitted to the lung cancer screening program on behalf of the participant during the emergency department visit.
The screening program will contact the participant to discuss screening and schedule a low dose CT scan if appropriate.
|
|
Experimental: Facilitated Referral plus Text Messaging
Participants assigned to this arm will receive facilitated referral plus the series of text messages described above.
Among these participants, contact with the lung cancer screening program is likely to occur after receipt of the initial text messages but prior to receipt of all text messages.
|
Participants receive a series of up to 9 theory informed text messages designed to increase awareness, motivation, and completion of lung cancer screening.
A lung cancer screening requisition form is submitted to the lung cancer screening program on behalf of the participant during the emergency department visit.
The screening program will contact the participant to discuss screening and schedule a low dose CT scan if appropriate.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Who Complete Lung Cancer Screening Within 120 Days After Enrollment
Prazo: Up to 120 Days After Enrollment
|
Lung cancer screening uptake is defined as completion of a low dose computed tomography scan for lung cancer screening within 120 days after enrollment.
Screening completion will be confirmed using electronic health record review, lung cancer screening program records, or participant self report obtained during follow up.
The outcome is reported as the proportion of participants who complete screening.
|
Up to 120 Days After Enrollment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Who Participate in Shared Decision Making for Lung Cancer Screening Within 120 Days After Enrollment
Prazo: Up to 120 Days After Enrollment
|
Participation in shared decision making is defined as documentation of a shared decision making discussion regarding lung cancer screening or participant self report of completing such a discussion within 120 days after enrollment.
The outcome is reported as the proportion of participants who participate in shared decision making.
|
Up to 120 Days After Enrollment
|
|
Frequency of Reported Barriers to Lung Cancer Screening at 120 Days
Prazo: 120 Days After Enrollment
|
Barriers to lung cancer screening are assessed using participant responses to a structured questionnaire administered at follow up.
The questionnaire includes items on transportation challenges, cost concerns, scheduling difficulties, and fear of screening results.
The outcome is reported as the number and proportion of participants reporting each barrier.
|
120 Days After Enrollment
|
|
Acceptability of Emergency Department Based Lung Cancer Screening Interventions at 120 Days
Prazo: Up to 120 Days After Enrollment
|
Acceptability is assessed using participant responses to Likert scale questionnaire items evaluating the degree to which participants find the emergency department based lung cancer screening interventions acceptable.
Each item is scored on a 5 point Likert scale ranging from 1 to 5, with higher scores indicating greater acceptability.
The outcome is reported as summary scores based on participant responses.
|
Up to 120 Days After Enrollment
|
|
Appropriateness of Emergency Department Based Lung Cancer Screening Interventions at 120 Days
Prazo: 120 Days After Enrollment
|
Appropriateness is assessed using participant responses to Likert scale questionnaire items evaluating the perceived fit and relevance of emergency department based lung cancer screening interventions.
Each item is scored on a 5 point Likert scale ranging from 1 to 5, with higher scores indicating greater perceived appropriateness.
The outcome is reported as summary scores based on participant responses.
|
120 Days After Enrollment
|
|
Frequency of Reported Facilitators to Lung Cancer Screening at 120 Days
Prazo: 120 Days After Enrollment
|
Facilitators to lung cancer screening are assessed using participant responses to a structured questionnaire administered at follow up.
The questionnaire includes items related to factors such as access to care, health literacy, prior healthcare engagement, and presence of a primary care provider.
The outcome is reported as the number and proportion of participants reporting each facilitator.
|
120 Days After Enrollment
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Estimado)
1 de março de 2027
Conclusão Primária (Estimado)
1 de dezembro de 2030
Conclusão do estudo (Estimado)
1 de dezembro de 2031
Datas de inscrição no estudo
Enviado pela primeira vez
27 de abril de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
28 de abril de 2026
Primeira postagem (Real)
5 de maio de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
5 de maio de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
28 de abril de 2026
Última verificação
1 de abril de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- FP00007604
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
INDECISO
Descrição do plano IPD
Undecided
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .